Immunosuppressive therapy for autoimmune bullous diseases

Clinics in Dermatology

Volumn 30, Issue 1, 2012, Pages 78-83

  Meurer, Michael ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; MESNA; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ADJUVANT THERAPY; ALOPECIA; AMENORRHEA; ANEMIA; ANOREXIA; APHERESIS; APHTHOUS STOMATITIS; ARTICLE; AUTOIMMUNE BULLOUS DISEASE; AZOOSPERMIA; BLADDER CARCINOMA; BLADDER DISEASE; BONE MARROW SUPPRESSION; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CANCER RISK; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; EPIDERMOLYSIS BULLOSA ACQUISITA; ERYTHEMA; ESOPHAGITIS; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GONADAL DISEASE; HAIR COLOR; HAIR DISEASE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; IMMUNOAPHERESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INFERTILITY; KIDNEY DISEASE; LETHARGY; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTOPENIA; LYMPHOMA; MACULOPAPULAR RASH; MUCOUS MEMBRANE PEMPHIGOID; MYALGIA; NAIL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NEUTROPENIA; PANCREATITIS; PANCYTOPENIA; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SHORT COURSE THERAPY; SIDE EFFECT; SKIN CANCER; SKIN PIGMENTATION; SKIN TOXICITY; STOMACH PAIN; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THROMBOSIS; TRANSITIONAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; VOMITING;

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; PEMPHIGOID, BULLOUS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SKIN DISEASES, VESICULOBULLOUS; TREATMENT OUTCOME;

EID: 83155160946     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2011.03.013     Document Type: Article

References (30)

1. Bystryn J.C., Steinman N.M. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996, 132:203-212.
2. Kirtschig G., Middleton P., Bennett C., Murrell D.F., Wojnarowska F. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010, CD002292.
3. Joly P., Roujeau J.C., Benichou J., Picard C., Dreno B. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346:321.
4. Hashimoto T. Treatment strategies for pemphigus vulgaris in Japan. Expert Opin Pharmacother 2008, 9:1519-1530.
5. Werth V.P. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol 1996, 132:1435-1439.
6. Mentink L.F., Mackenzie M.W., Tóth G.G., Laseur M., Lambert F.P. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol 2006, 142:570-576.
7. Harman K.E., Albert S., Black M.M. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003, 149:926-937.
8. Aberer W., Wolff-Schreiner E.C., Stingl G., Wolff K. Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. J Am Acad Dermatol 1987, 16:527-533.
9. Anstey A.C.V., Wakelin S., Reynolds N.J. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004, 151:1123-1132.
10. Schiavo A.L., Puca R.V., Ruocco V., Ruocco E. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety. Facts and controversies. Clin Dermatol 2010, 28:337-343.
11. Sandborn W.J. State-of-the-art: immunosuppression and biologic therapy. Dig Dis 2010, 28:536-542.
12. Burton J.L., Harman R.R., Peachey R.D., Warin R.P. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J 1978, 2:1190-1191.
13. Chams-Davatchi C., Esmaili N., Daneshpazhooh M., Valikhani M., Balighi K., Hallaji Z. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007, 57:622-628.
14. Enk A.H., Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997, 350:494.
15. Enk A.H., Knop J. Mycophenolate is effective in treatment of pemphigus vulgaris. Arch Dermatol 1999, 135:54-56.
16. Powell A.M., Albert S., Al Fares S., Harman K.E., Setterfield J. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol 2003, 149:138-145.
17. Strowd L.C., Taylor S.L., Jorizzo J.L., Namazi M.R. Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. J Am Acad Dermatol 2011, 64:490-494.
18. Böhm M., Beissert S., Schwarz T., Metze D., Luger T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997, 349:541.
19. Nousari H.C., Griffin W.A., Anhalt G.J. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol 1998, 39:497-498.
20. Grundmann-Kollmann M., Korting H.C., Behrens S., Kaskel P., Leiter U. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999, 40:957-960.
21. Beissert S., Werfel T., Frieling U., Böhm M., Sticherling M. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007, 143:1536-1542.
22. Beissert S., Mimouni D., Kanwar A.J., Solomons N., Kalia V., Anhalt G.J. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010, 130:2041-2048.
23. Bongiorno M.R., Pistone G., Doukaki S., Aricò M. Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus. Int J Dermatol 2010, 49:693-699.
24. Fleischli M.E., Valek R.H., Pandya A.G. Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol 1999, 135:57-61.
25. Hertl M., Zillikens D., Borradori L., Bruckner-Tuderman L., Burckhard H. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008, 6:366-373.
26. Zillikens D., Derfler K., Eming R., Fierlbeck G., Goebeler M. Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007, 5:881-887.
27. Griffiths C.E., Katsambas A., Dijkmans B.A., Finlay A.Y., Ho V.C. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol 2006, 155(suppl 2):1-16.
28. Martin L.K., Werth V., Villanueva E., Segall J., Murrell D.F. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009, CD006263.2009.
29. Smith T.J., Bystryn J.C. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol 1999, 135:1275-1276.
30. Hofmann S.C., Kautz O., Hertl M., Sticherling M., Zillikens D. Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J Dtsch Dermatol Ges 2009, 7:227-233.